The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|June 26, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014
- Volume 10
- Issue 7
Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug
Author(s)Pharmaceutical Technology Editors
Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.
Advertisement
Medicenna Therapeutics, a clinical stage immune-oncology company, has selected
Kalon’s first project with Medicenna is for a clinical trial testing the effectiveness of Medicenna’s empowered cytokines (ECs) for children with brain cancer. The agreement provides for Kalon to manufacture the material that will be used in human clinical trials in children and adults with brain cancer.
Source:
Articles in this issue
over 12 years ago
GSK Offers $1 Million Award for Healthcare Innovationsover 12 years ago
Covance MarketPlace Connects Biotech with Potential Partnersover 12 years ago
Pharma Capacity to Produce Cytotoxic Injectable Drugs Constrictsover 12 years ago
Changing Market Dynamics Require New Approaches to Innovationover 12 years ago
Cost Is No Longer the Driving Force for Outsourcingover 12 years ago
Cytovance Biologics Manufactures AM0010 for ARMO BioSciencesover 12 years ago
Globalization Challenges Drug Regulatorsover 12 years ago
Aesica Pharmaceuticals S.r.I. Implements Serialization Systemover 12 years ago
Frontage Labs Plans Expansion of CMC Facilityover 12 years ago
Novartis Hosts 13th Annual Malaria Expert PanelAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement